Second phase I trial of ORADUR-ADHD.

Trial Profile

Second phase I trial of ORADUR-ADHD.

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Aug 2013

At a glance

  • Drugs Methylphenidate (Primary)
  • Indications Attention-deficit hyperactivity disorder
  • Focus Adverse reactions
  • Most Recent Events

    • 01 Aug 2013 Methylphenidate was disclosed as an agent evaluated in this trial. Methylphenidate is the lead agent in the ORADUR-ADHD programme.
    • 04 Nov 2011 Status changed from planning to completed.
    • 01 Jun 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top